Four-year epidemiological study of extended-spectrum β-lactamase-producing Enterobacteriaceae in a French teaching hospital

Clinical Microbiology and Infection

Volumn 20, Issue 1, 2014, Pages

  Gibold, L ^a,b   Robin, F ^a,b,c   Tan, R N ^a,c   Delmas, J ^a,b   Bonnet, R ^a,b,c  

^a UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c Centre National de Référence de la Résistance Aux Antibiotiques   (France)

Author keywords

Antibiotic resistance; Enterobacteriaceae; Escherichia coli; Extended spectrum lactamase; lactamase

Indexed keywords

AMINOGLYCOSIDE; AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAMASE CTX M; CARBAPENEM DERIVATIVE; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN; COLISTIN; COTRIMOXAZOLE; ERTAPENEM; FOSFOMYCIN; FURAN DERIVATIVE; IMIPENEM; MEROPENEM; NITROFURAN DERIVATIVE; PENICILLIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TIGECYCLINE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM ISOLATE; BACTERIUM ISOLATION; EMERGENCY WARD; ENTEROBACTERIACEAE INFECTION; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HUMAN; INCIDENCE; INFECTION RISK; NONHUMAN; PREVALENCE; PRIORITY JOURNAL; TEACHING HOSPITAL;

ENTEROBACTERIACEAE; ESCHERICHIA COLI;

ANTIBIOTIC RESISTANCE; ENTEROBACTERIACEAE; ESCHERICHIA COLI; EXTENDED-SPECTRUM Β-LACTAMASE; Β-LACTAMASE;

ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; COMMUNITY-ACQUIRED INFECTIONS; DRUG RESISTANCE, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ESCHERICHIA COLI; ESCHERICHIA COLI INFECTIONS; FLUOROQUINOLONES; FOSFOMYCIN; FRANCE; FURANS; HOSPITALS, TEACHING; HUMANS; MICROBIAL SENSITIVITY TESTS; RETROSPECTIVE STUDIES;

EID: 84890805813     PISSN: 1198743X     EISSN: 14690691     Source Type: Journal    
DOI: 10.1111/1469-0691.12321     Document Type: Article

References (31)

1. Bradford PA. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 2001; 14: 933-951, table of contents.
2. Livermore DM, Yuan M. Antibiotic resistance and production of extended-spectrum beta-lactamases amongst Klebsiella spp. from intensive care units in Europe. J Antimicrob Chemother 1996; 38: 409-424.
3. Cantón R, Oliver A, Coque TM, Varela Mdel C, Pérez-Díaz JC, Baquero F. Epidemiology of extended-spectrum β-lactamase-Producing Enterobacter isolates in a Spanish hospital during a 12-Year Period. J Clin Microbiol 2002; 40: 1237-1243.
4. Bonnet R. Growing group of extended-spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48: 1-14.
5. Hawkey PM, Jones AM. The changing epidemiology of resistance. J Antimicrob Chemother 2009; 64(suppl 1): i3-i10.
6. Livermore DM, Canton R, Gniadkowski M et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59: 165-174.
7. Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill 2008; 13: 1-11.
8. Rodriguez-Bano J, Navarro MD, Romero L et al. Bacteremia due to extended-spectrum beta -lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006; 43: 1407-1414.
9. Cai JC, Zhou HW, Zhang R, Chen GX. Emergence of Serratia marcescens, Klebsiella pneumoniae, and Escherichia coli Isolates possessing the plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC-2 in intensive care units of a Chinese hospital. Antimicrob Agents Chemother 2008; 52: 2014-2018.
10. Oteo J, Delgado-Iribarren A, Vega D et al. Emergence of imipenem resistance in clinical Escherichia coli during therapy. Int J Antimicrob Agents 2008; 32: 534-537.
11. Recommandations du comité de l'antibiogramme de la société française de microbiologie. 2009. Available from: http://www.sfm-microbiologie.org.
12. Bonnet R, Sampaio JL, Chanal C et al. A novel class A extended-spectrum beta-lactamase (BES-1) in Serratia marcescens isolated in Brazil. Antimicrob Agents Chemother 2000; 44: 3061-3068.
13. De Champs C, Chanal C, Sirot D et al. Frequency and diversity of Class A extended-spectrum beta-lactamases in hospitals of the Auvergne, France: a 2 year prospective study. J Antimicrob Chemother 2004; 54: 634-639.
14. Observatoire national de l'epidémiologie de la résistance bactérienne aux antibiotiques (ONERBA). Rapport d'activité 2008/Annual Report 2008. Vivactis Plus Ed 2010 Available from: http://www.onerba.org
15. D'Agata EM. Rapidly rising prevalence of nosocomial multidrug-resistant, Gram-negative bacilli: a 9-year surveillance study. Infect Control Hosp Epidemiol 2004; 25: 842-846.
16. Jarlier V, Arnaud I, Carbonne A. Surveillance des bactéries multirésistantes dans les établissements de santé en France. Réseau BMR-Raisin. Résultats 2009. Saint-Maurice: Institut de veille sanitaire; 2011. Available from: http://www.invs.sante.fr
17. Grabe M, Bishop MC, Bjerklund-Johansen TE et al. Guidelines on urological infections. EAU Guidelines edition presented at the 25th EAU Annual Congress C1 - Barcelona 2010.
18. Gupta K, Hooton TM, Naber KG et al. International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis 2011; 52: e103-e120.
19. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9: 466-475.
20. Moreno A, Bello H, Guggiana D, Dominguez M, Gonzalez G. Extended-spectrum beta-lactamases belonging to CTX-M group produced by Escherichia coli strains isolated from companion animals treated with enrofloxacin. Vet Microbiol 2008; 129: 203-208.
21. Rodriguez-Bano J, Lopez-Cerero L, Navarro MD, Diaz de Alba P, Pascual A. Faecal carriage of extended-spectrum beta-lactamase-producing Escherichia coli: prevalence, risk factors and molecular epidemiology. J Antimicrob Chemother 2008; 62: 1142-1149.
22. Valverde A, Coque TM, Sanchez-Moreno MP, Rollan A, Baquero F, Canton R. Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain. J Clin Microbiol 2004; 42: 4769-4775.
23. Hunter PA, Dawson S, French GL et al. Antimicrobial-resistant pathogens in animals and man: prescribing, practices and policies. J Antimicrob Chemother 2010; 65(suppl 1): i3-i17.
24. Machado E, Coque TM, Canton R et al. Leakage into Portuguese aquatic environments of extended-spectrum-beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 2009; 63: 616-618.
25. Oguri S, Matsuo J, Hayashi Y et al. Ciliates promote the transfer of the gene encoding the extended-spectrum beta-lactamase CTX-M-27 between Escherichia coli strains. J Antimicrob Chemother 2011; 66: 527-530.
26. Aumeran C, Poincloux L, Souweine B et al. Multidrug-resistant Klebsiella pneumoniae outbreak after endoscopic retrograde cholangiopancreatography. Endoscopy 2010; 42: 895-899.
27. Randrianirina F, Vedy S, Rakotovao D et al. Role of contaminated aspiration tubes in nosocomial outbreak of Klebsiella pneumoniae producing SHV-2 and CTX-M-15 extended-spectrum beta-lactamases. J Hosp Infect 2009; 72: 23-29.
28. Ben-Ami R, Rodríguez-Baño J, Arslan H et al. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing Enterobacteriaceae in nonhospitalized patients. Clin Infect Dis 2009; 49: 682-690.
29. Paterson DL, Bonomo RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005; 18: 657-686.
30. Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17: 1791-1798.
31. Nordmann P. Gram-negative bacteriae with resistance to carbapenems. Med Sci (Paris) 2010; 26: 950-959.